Pacira
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
2000 Sierra Point Pkwy Ste 900, Brisbane...Phone Number
(855) 793-9727Website
www.pacira.comRevenue
$746.2 MillionStock Symbol
PCRXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
2
2
1
1
1
About Pacira
Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes. We have a drive and a desire to improve the world around us and make a meaningful difference in the lives of patients, families, communities, and society. (Nasdaq: PCRX) is a provider of non-opioid pain management and regenerative health solutions manufacturing.Explore more
Pacira Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pacira your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Pacira had a recent Job posting/layoffs
Check out if Pacira is spiking on competitors!
Funding: Get notified immidiatlly once Pacira has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Pacira launches new products
Pacira, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Pacira has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Pacira recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Pacira
Recommended Actions
Reach out to Masked Content who joined Pacira as Masked Content
Find 2 more new buyers
Compare Similar Companies to Pacira
Compare insights from companies similar to Pacira, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Pacira is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pacira is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pacira.
Pacira financials insights
Gather financial insights about Pacira, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Stock Offering
$42M
Pacira Tech Stack
A closer look at the technologies used by Pacira
See more technologies
Most Recent Scoops
Project
Pacira announced that LG Chem has filed for regulatory approval for EXPAREL in South Korea, with revenues expected to begin in 2027, as part of Pacira's commercial partnerships outside the US that are expected to extend through the life of its patents providing exclusivity into the 2040s.
Pharmaceuticals
Project
Pacira has initiated enrollment in Part B of the Phase II study for PCRX-201, with top-line results for Part A which randomized 49 patients across three treatment groups with a primary objective of safety and secondary efficacy endpoints evaluated at weeks 38 and 52 expected later this year.
Pharmaceuticals, Clinical Operations
Person-Based
Kristen Williams participated in Pacira Q2 2026 earnings conference call on Tuesday, August 4, 2026.
Earnings, Finance
Person-Based
Earnings, Finance
Person-Based
Pacira News & Media
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on August 4, 2026 to five new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing RulePacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis —Pacira BioSciences Reports Second Quarter 2026 Financial Results
-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships -- -- Delivered second quarter total revenue of $192.4 million, representing 6 percent year-over-year growth --Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce
- Survey findings highlight the prevalence of knee pain, reported impacts on work and quality of life, and strong interest in long-lasting, non-opioid treatment options -
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pacira
Sign Up For FreeTo access detailed company insights
Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes. We have a drive and a desire to improve the world around us and make a meaningful difference in the lives of patients, families, communities, and society. (Nasdaq: PCRX) is a provider of non-opioid pa... Read More
